PetIQ Acquires MYOS, a Clinically-Studied Portfolio of Muscle Health Products that Support Muscle Preservation, Injury Recovery, and Healthy Aging for Pets

PetIQ, Inc., a prominent player in the pet health and wellness sector, has finalized the acquisition of MYOS Corp, a bio nutrition company known for its Fortetropin®-based product portfolio. The transaction, which took place on July 29, 2026, involves an undisclosed amount and is anticipated to enhance PetIQ's offerings in the rapidly growing pet health market.

The acquisition of MYOS Corp is strategically significant for PetIQ as it strengthens its position in the pet health and wellness industry. MYOS brings to the table a clinically-studied muscle health brand, along with patented ingredient technology that supports muscle growth and preservation. Fortetropin®, the proprietary ingredient at the core of MYOS's products, has been shown to modulate myostatin, a natural regulator of muscle mass, thereby promoting muscle health in companion animals. This addition allows PetIQ to tap into the burgeoning muscle health category, catering to the increasing demand among pet owners for preventive health solutions that enhance their pets' quality of life.

MYOS has a decade-long history of collaboration with veterinarians, which has informed the development of its products. The company’s focus on muscle health aligns with a broader trend in the pet care industry, where pet owners are increasingly seeking out products that support mobility and recovery rather than merely addressing health issues post-factum. The integration of MYOS’s offerings into PetIQ’s existing portfolio will enable the company to provide a more comprehensive suite of health and wellness products, thereby enhancing its competitive edge in the market.

PetIQ, backed by Bansk Group, has established itself as a leading provider of over-the-counter pet medications and wellness products. With a diverse range of brands, including PetArmor® and VetIQ®, the company is well-positioned to leverage its extensive distribution network to scale MYOS's product lines. The partnership is expected to enhance MYOS's reach and visibility in the market, allowing it to capitalize on PetIQ's established retail and e-commerce channels.

The acquisition of MYOS Corp reflects broader dynamics within the pet health sector, which continues to evolve as pet owners prioritize preventive care and wellness solutions. As the market for pet health and wellness products expands, companies like PetIQ that invest in innovative and clinically supported offerings are likely to benefit from increased consumer interest. This transaction not only underscores PetIQ's commitment to enhancing its product portfolio but also highlights the growing importance of muscle health in the overall pet wellness landscape.